coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Similar documents
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Fig. 1 Chemical structure of DL-8280

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human



epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote


Fig. 1 Chemical structure of KW-1070

VOL.42 S-1

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


CHEMOTHERAPY

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of norfioxacin (AM-715)

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.1 Chemical structure of BAY o 9867

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1



Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium





988 CHEMOTHERAPY NOV. 1971

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

Table1MIC of BAY o 9867 against standard strains


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s


VOL. 34 S-2 CHEMOTH8RAPY 913


Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

日本化学療法学会雑誌第53巻第S-3号


VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

1272 CHEMOTHERAPY MAR. 1975

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum



VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY SEPT. 1970

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

日本化学療法学会雑誌第55巻第S-1号


CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K


VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of

M CHEMOTHERAPY DEC ciprofloxacin(cpfx), ofloxacin(oflx) Staphylococcus aureus, Streptococcus pneumoniae Bacteroides fragi. Haemophilus influenza

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY JUNE 1986

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3



CHEMOTHERAPY SEPT. 1991

Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)


THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

co Kanamycin (KM), Streptomycin (SM), Fradiomycin Table 2. Comparison of antibacterial activity of 3', 4'-dideoxykanamycin B with that of other antibi

VOL. 36 S-3 CHEMOTHERAPY 437

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC


VOL.39 S-3

日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

Transcription:

VOL.43 S-1

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin in serum and pleural fluid after a single dose of 200 mg

Table 2-1. Clinical summary of grepafloxacin treatment

Table 2-2. Clinical summary of grepafloxacin treatment Table 3. Clinical effect of grepafloxacin Table 4. Bacteriological effect of grepafloxacin

Table 5. Laboratory findings in patients before and after administration of grepafloxacin

6) Ohmori K, Kuramoto M, Mukai F, Tamaoka H and Kikuchi M: OPC-17116; a novel broad-spectrum 5-methyl quinolone derivative: Therapeutic effects against variuos infections in amimals. 31st 1) OPC-17116. Drugs of Future 17: 286 `290 1992 2) Imada T, Miyazaki S, Nishida M, Yamaguchi K and Goto S: In vitro and in vivo antibacterial activities of new quinolone, OPC-17116. Antimicrob Agents Chemother 36: 573-579, 1992 3) Neu H C, Fang W, Gu J and Chin N: In vitro activity of OPC-17116. Antimicrob Agents Chemother 36: 1310-1315, 1992 4) Wakebe H and Mitsuhashi S: Comparative in vitro activities of a new quinolone, OPC-17116, possesing potent activity against gram-positive bacteria. Antimicrob Agents Chemother 36: 2185 `191, 1992 ICAAC, abstract no. 1475, Chicago, October, 1991 9) Taira K, Koga H and Kohno S: Accumulation of a new developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 37: 1877-1881, 1993,

Penetration into pleural fluid and clinical evaluation of grepafloxacin for respiratory tract infections Harumi Shishido, Koji Hayashi, Hideaki Nagai, Shuji Miyake, Kenji Kawakami, Atsuyuki Kurashima and Koji Satoh Department of Respiratory Diseases, Tokyo National Chest Hospital 3-1-1 Takeoka, Kiyose, Tokyo 204, Japan We studied the penetration into plueral fluid of grepafloxacin (GPFX) and evaluated its clinical efficacy for respiratory tract infections. The penetration rate of GPFX into pleural fluid (ratio of maximum pleural fluid concentration to peak serum concentration) determined by thehplc method in 3 patients with pleural fluid was 33.3-50.5% (mean: 43.5%). A similar result was obtained by bioassay. The efficacy rate (more effective) for 24 cases with respiratory infection was 95.7% after oral administration of GPFX. Bacteriologically, 19 strains were isolated, including 5 strains of Staphylococcus aureus, 3 strains of Haemophilus influenzae, 1 strain of Klebsiella pneumoniae, 3 strains of Pseudomonas aeruginosa, 1 strain of Xanthomonas maltophilia and 1 strain of Corynebacterium sp. and so on. Sixteen strains (except for 2 strain of S. aureus and 1 strains of P. aeruginosa) were eradicated, an eradication rate of 84.2%. No side effect was observed in any of the cases examined. In the laboratory tests, however, slightly elevated s-got and s-gpt were observed in 1 case. Based on the above results, GPFX is considered a useful new quinolone derivative for the treatment of respiratory tract infections.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック